By Bob Huff The Indian generic pharmaceutical industry, operating under Indian patent laws that permitted liberal copying of medicines, made possible the revolution in antiretroviral treatment access that has occurred in Africa since 2001. In April, 25 treatment activists from…
By Bob Huff Online webcasts make CROI (the Conference on Retroviruses and Opportunistic Infections) the most accessible major scientific meeting on AIDS. Webcasts are accessed through the main website at www.retroconference.org/2008. Click on View the Webcasts and Podcasts. The webcast…
Comments by Mark Harrington, executive director of Treatment Action Group, for the Ford Foundation–hosted meeting on developing a national AIDS strategy for the United States In April 2008, the Ford Foundation hosted a meeting of over 40 national AIDS leaders…
Hopes Dim for Struggling Field By Richard Jefferys Immunizations in a trial of Merck's HIV vaccine were stopped when it was determined that the vaccine was not working. There are now concerns that the vaccine may have increased the risk…
By Theo Smart and Javid Syed A TAG-sponsored forum in South Africa brought together scientists, policy makers, and community activists to discuss multidrug resistant and extensively drug resistant TB and HIV and to identify steps to address the growing crisis…
Scientists at conference examine barriers to curing HIV infection. TAG proposes a workshop in 2008 to move these efforts forward. The HIV persistence workshop is a biannual event held on the small Caribbean island of St. Maarten. The goal of…
New Surveillance Networks Needed By Tracy Swan Recent outbreaks of acute hepatitis C virus (HCV) among HIV-positive men who have sex with men (MSM) have been reported in England, France, Germany, Holland, and the United States. Many of these cases…
In March 2007, a group of community activists, many living with HIV and hepatitis C virus (HCV), gathered with researchers, doctors, regulators, and representatives from Abbott, Roche, Schering, and Tibotec, in Sitges, Spain, at a meeting held by the European…
Drug Company $ Million Change From 2005 Notes Truvada Gilead 1,194 +210% Kaletra Abbott 1,135 +13% Combivir GlaxoSmithKline 977 -8% Reyataz Bristol-Myers Squibb 931 +34% Sustiva Bristol-Myers Squibb 791 +16% Includes $76 million related to Atripla sales Viread Gilead 689…
More Than Just Markers By Richard Jefferys "... no longer solely of interest to academic immunologists ..." At the recent International AIDS Society conference in Sydney, Mike Lederman reminded attendees that abnormally high levels of immune activation were described in the first…